SCHEMBL1108273

SCHEMBL1108273

C=CCOCc1cc(Nc2nccc(-c3cccc(OCC=C)c3)n2)ccc1OCCN1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AIMP2 Q13155 1/20 0.47
ABL1 P00519 5/20 0.44
BCR P11274 5/20 0.44
SRC P12931 3/20 0.43
EGFR P00533 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCD Q05655 1/20 0.43
SYK P43405 2/20 0.42
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
MAP4K4 O95819 1/20 0.40
PRKCQ Q04759 1/20 0.40
JAK2 O60674 2/20 0.39
JAK3 P52333 1/20 0.39
CAMK2D Q13557 1/20 0.39
LTA4H P09960 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
BACE1 P56817 1/20 0.38
MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098407 0.92 ABL1 (0.43) AIMP2ABL1BCRSRCEGFR
SCHEMBL14023511 0.89 ABL1 (0.40) AIMP2ABL1BCRSYKCCNA2
SCHEMBL14845405 0.89 ABL1 (0.41) AIMP2ABL1BCRSRCEGFR
SCHEMBL4751809 0.88 ABL1 (0.42) AIMP2ABL1BCRSYKJAK2
SCHEMBL4749275 0.85 ABL1 (0.39) AIMP2ABL1BCRSRCSYK
SCHEMBL1098894 0.85 SYK (0.40) AIMP2ABL1BCRSYKJAK2
SCHEMBL14022857 0.85 IGF1R (0.40) AIMP2ABL1BCRSRCEGFR
SCHEMBL1098622 0.85 ABL1 (0.40) AIMP2ABL1BCRSYKCDK2
SCHEMBL4856403 0.83 AIMP2 (0.38) AIMP2ABL1BCREGFRSYK
SCHEMBL1099020 0.83 JAK2 (0.43) AIMP2ABL1BCRSYKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135227-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2021-10-05 US disclosed
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2020-03-05 US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 US disclosed
EP-1951729-B1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS INC (US) 2014-06-25 EP disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 AIMP2 2979/4885ABL1 343/4885BCR 1521/4885
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 AIMP2 2979/4885ABL1 343/4885BCR 1521/4885
US-11135227-B2 Oxygen linked pyrimidine derivatives DPYD, TK2, TK1 AIMP2 2979/4885ABL1 343/4885BCR 1521/4885
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 AIMP2 2979/4885ABL1 343/4885BCR 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.